Comphya has raised CHF 3 million from investiere and private investors. investiere contributed CHF 1.1 million to this round. 

Erectile dysfunction is a disorder affecting 66 million people in the EU and US. 30% of patients do not respond to drugs like Viagra, e.g. due to disrupted nerves from spinal cord injury or prostate removal. These patients have to use painful methods such as injections or penile implants. EPFL spinoff Comphya is developing a painless alternative, an implanted neurostimulator in the pelvic cavity which can be activated via remote control. In a first surgery trial with 20 patients, Comphya achieved a response rate of 100% and has already garnered the support of key opinion leaders. “The only available alternatives penile implants and injections, are outdated, very painful and have side effects”, explains Susanne Schorsch, investiere’s investment manager responsible for the case. With the funding, Comphya will continue developing its product and conduct clinical trials to show its efficacity.